Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
11 sept. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
07 sept. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
14 août 2023 16h00 HE
|
Achieve Life Sciences
Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:...
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
01 août 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
18 juil. 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
11 juil. 2023 11h23 HE
|
Achieve Life Sciences
Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability” Supports potential for cytisinicline to be the first...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
06 juin 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
25 mai 2023 09h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
23 mai 2023 06h00 HE
|
Achieve Life Sciences
ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo ...
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
17 mai 2023 08h00 HE
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...